Promising phase 2B trial results of Lanifibranor in NASH
During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment.
Speaker: Prof. Sven Francque
Host: Dr. Manuel Castro Cabezas
Co-host: Prof. Christophe Moreno
Related webinars
Webinar: Lifestyle Interventions in NAFLD/NASH
On the 19th of September, we presented the 9th webinar of our NASH Webinar Series. During this webinar, speaker Professor Zelber-Sagi explored the relationship between diet and NAFLD, emphasizing that diet not only causes NAFLD but can also serve ...
Webinar: Why NASH trials frequently fail and how to improve them
On May 23, we presented the webinar: Why NASH trials frequently fail and how to improve them Guest speaker: Professor Manuel Castro Cabezas Host: Professor Diederick E. Grobbee Fill in the form and watch the replay: ...
Getting GRIP on NASH: Implementation of an international screening program
During the 5th Global NASH Congress in London, Our Chief Scientific Officer Prof. Dr. D.E. Grobbee was one of the speakers and presented: Getting GRIP on NASH; Implementation of an International Clinical Screening Program. During this presentat...